Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.23−0.46 (-5.29%)
Close on Nov 18, 2026Market cap $239.70MP/E –Yield –
Enanta Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Enanta Pharmaceuticals's revenue for the twelve months ending Sep 30, 2026 was $63.00M, down 3.6% year over year. For fiscal 2026 it was $63.00M, down 3.6% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $206.63M in fiscal 2018.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | $63.00M | -3.6% |
| FY2025 | Sep 30, 2025 | $65.32M | -3.4% |
| FY2024 | Sep 30, 2024 | $67.64M | -14.6% |
| FY2023 | Sep 30, 2023 | $79.20M | -8.1% |
| FY2022 | Sep 30, 2022 | $86.16M | -11.2% |
| FY2021 | Sep 30, 2021 | $97.07M | -20.7% |
| FY2020 | Sep 30, 2020 | $122.47M | -40.3% |
| FY2019 | Sep 30, 2019 | $205.20M | -0.7% |
| FY2018 | Sep 30, 2018 | $206.63M | +101.0% |
| FY2017 | Sep 30, 2017 | $102.81M | +16.5% |
| FY2016 | Sep 30, 2016 | $88.27M | -45.1% |
| FY2015 | Sep 30, 2015 | $160.88M | +237.0% |
| FY2014 | Sep 30, 2014 | $47.74M | +48.9% |
| FY2013 | Sep 30, 2013 | $32.05M | -23.1% |
| FY2012 | Sep 30, 2012 | $41.71M | -0.4% |
| FY2011 | Sep 30, 2011 | $41.88M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | $12.87M | -14.9% |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $14.36M | -15.3% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $17.16M | +17.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $18.62M | +3.6% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $15.13M | -11.3% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $16.96M | -5.8% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $14.61M | -22.8% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $17.97M | -4.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $17.05M | -4.2% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $18.00M | -23.7% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $18.93M | -6.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $18.89M | -3.0% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $17.80M | -4.9% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $23.59M | -14.7% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $20.32M | -13.8% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $19.48M | -9.9% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $18.72M | -7.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $27.65M | -12.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $23.58M | -0.2% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $21.62M | +15.9% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $20.13M | -27.1% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $31.74M | -39.6% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $23.63M | -53.9% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $18.65M | -58.0% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $27.62M | -30.3% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $52.57M | -24.8% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $51.31M | -23.6% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $44.37M | -22.5% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $39.63M | -10.0% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $69.89M | +83.4% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $67.21M | -11.5% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $57.26M | +662.4% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $44.05M | +391.7% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $38.11M | +265.8% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $75.93M | +491.3% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $7.51M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $8.96M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $10.42M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $12.84M | – |
See a number that looks wrong?